Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers
Read Article
Monoceros Biosystems, a leading bioinformatics/computational biology provider, is pleased to announce the appointment of Regan Lohman to its Board of Directors
We are thrilled to announce the appointment of Regan Lohman [...]
Monoceros Biosystems and SeekIn Join Forces to Pave the Way for Cutting-Edge AI-Powered Cancer Diagnostics
San Diego, September 21, 2023 – Monoceros Biosystems, a prominent [...]
MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
Mirati Therapeutics, in collaboration with Monoceros Biosystems and leading academic [...]
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
Mirati Therapeutics, in collaboration with Array BioPharma (Pfizer) and Monoceros [...]
The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Mirati Therapeutics, in collaboration with additional groups including Monoceros Biosystems, [...]
Monoceros Biosystems: Bringing Professional Grade Bioinformatics to All
Monoceros Biosystems has been selected as a top 10 bioinformatics [...]
Monoceros Biosystems, a top bioinformatics/computational biology industry partner, is pleased to announce the appointment of John Lamb, PhD and Dan Rawlins, JD to its Advisory Board
Monoceros Biosystems LLC is pleased to announce that John Lamb, [...]